Journal article

Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study

Liubov Robman, Robyn Guymer, Robyn Woods, Stephanie Ward, Rory Wolfe, James Phung, Lauren Hodgson, Galina Makeyeva, Khin Zaw Aung, Tom Gilbert, Jessica Lockery, Y-Anh Le-Pham, Suzanne Orchard, Elsdon Storey, Walter Abhayaratna, Daniel Reid, Michael E Ernst, Mark Nelson, Christopher Reid, John McNeil

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS | ELSEVIER INC | Published : 2017

Abstract

PURPOSE: Although aspirin therapy is used widely in older adults for prevention of cardiovascular disease, its impact on the incidence, progression and severity of age-related macular degeneration (AMD) is uncertain. The effect of low-dose aspirin on the course of AMD will be evaluated in this clinical trial. DESIGN: A sub-study of the 'ASPirin in Reducing Events in the Elderly' (ASPREE) trial, ASPREE-AMD is a 5-year follow-up double-blind, placebo-controlled, randomized trial of the effect of 100 mg daily aspirin on the course of AMD in 5000 subjects aged 70 years or older, with normal cognitive function and without cardiovascular disease at baseline. Non-mydriatic fundus photography will b..

View full abstract

Grants

Awarded by National Health and Medical Research Council, Australia (NHMRC)


Awarded by National Institutes of Health (NIH) through the National Institute on Aging


Awarded by NATIONAL EYE INSTITUTE


Awarded by NATIONAL INSTITUTE ON AGING


Funding Acknowledgements

The principal ASPREE study has been supported by the National Health and Medical Research Council, Australia (NHMRC) [grant #334047], the National Institutes of Health (NIH) through the National Institute on Aging [grant #RO1-AG029824], the Victorian Cancer Agency (Victorian Government, Australia) and Monash University.